Join        Login             Stock Quote

Athenahealth (ATHN) To Buy Epocrates (EPOC) For 22 Pct Premium

 January 07, 2013 09:18 AM

(By Balaseshan) Athenahealth Inc. (NASDAQ: ATHN), which provides ongoing billing, clinical-related and other related services, said it has agreed to buy mobile drug reference tools provider Epocrates Inc. (NASDAQ: EPOC) for about $293 million.

Athenahealth will pay Epocrates $11.75 per share in cash, representing a 22% premium over the Friday's closing price. This is an all-cash offer for all outstanding shares of Epocrates' common stock, and Athenahealth plans to finance this acquisition using available cash and funds available from its existing credit facility.

[Related -Analysts' Rating And Target Changes: AET, ATHN, CRM, DST, DWA, IDCC, MCD]

Epocrates shareholders representing about 17.5% of the outstanding common stock have agreed to vote their shares in favor of the transaction.

With the acquisition of Epocrates, which is used and trusted by more than 330,000 physicians, Athenahealth believes it will be able to better serve an expanded network of providers.

Athenahealth intends to build upon Epocrates' success to date in transforming the way physicians access and engage with clinical information, with each other, and with their patients.

Piper Jaffray & Co. acted as exclusive financial advisor to Epocrates in connection with the transaction. Goodwin Procter LLP served as Athenahealth's legal counsel and Cooley LLP served as counsel to Epocrates.

[Related -Athenahealth (ATHN): Feeling The Squeeze From ACOs]

The closing of the transaction is subject to the approval of Epocrates shareholders and other customary closing conditions and is currently expected to occur early in the second quarter of 2013.

ATHN closed Friday's regular session at $76.35, while EPOC ended at $9.62.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageInitial Jobless Claims Rose Unexpectedly

Claims unexpectedly rose in the latest report through last weekend to breach 300,000 for the first time read on...

article imageAll Quiet on the Record High Front

What can we glean from the media’s lack of attention to the market’s recent record read on...

article imageThe Chip Maker Short Sellers Should Be Watching

Investing in semiconductor stocks is always tricky. Industry cycles can lead to bumps in the road for the read on...

article imageChicago Fed: US Economic Growth Slowed In October

The pace of US growth slowed more than expected in October, according to this morning’s update of the read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.